312 related articles for article (PubMed ID: 23194438)
1. Gut Pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes.
Saad R; Rizkallah MR; Aziz RK
Gut Pathog; 2012 Nov; 4(1):16. PubMed ID: 23194438
[TBL] [Abstract][Full Text] [Related]
2. Toxicomicrobiomics: The Human Microbiome vs. Pharmaceutical, Dietary, and Environmental Xenobiotics.
Abdelsalam NA; Ramadan AT; ElRakaiby MT; Aziz RK
Front Pharmacol; 2020; 11():390. PubMed ID: 32372951
[TBL] [Abstract][Full Text] [Related]
3. Pharmacomicrobiomics: Influence of gut microbiota on drug and xenobiotic metabolism.
Dikeocha IJ; Al-Kabsi AM; Miftahussurur M; Alshawsh MA
FASEB J; 2022 Jun; 36(6):e22350. PubMed ID: 35579628
[TBL] [Abstract][Full Text] [Related]
4. Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response?
Sharma A; Buschmann MM; Gilbert JA
Clin Pharmacol Ther; 2019 Aug; 106(2):317-328. PubMed ID: 30937887
[TBL] [Abstract][Full Text] [Related]
5. Pharmacomicrobiomics: the impact of human microbiome variations on systems pharmacology and personalized therapeutics.
ElRakaiby M; Dutilh BE; Rizkallah MR; Boleij A; Cole JN; Aziz RK
OMICS; 2014 Jul; 18(7):402-14. PubMed ID: 24785449
[TBL] [Abstract][Full Text] [Related]
6. Human Gut Microbiota and Drug Metabolism.
Pant A; Maiti TK; Mahajan D; Das B
Microb Ecol; 2023 Jul; 86(1):97-111. PubMed ID: 35869999
[TBL] [Abstract][Full Text] [Related]
7. Adjusting for age improves identification of gut microbiome alterations in multiple diseases.
Ghosh TS; Das M; Jeffery IB; O'Toole PW
Elife; 2020 Mar; 9():. PubMed ID: 32159510
[TBL] [Abstract][Full Text] [Related]
8. Interplays between drugs and the gut microbiome.
Wan Y; Zuo T
Gastroenterol Rep (Oxf); 2022; 10():goac009. PubMed ID: 35401987
[TBL] [Abstract][Full Text] [Related]
9. Drug response in association with pharmacogenomics and pharmacomicrobiomics: towards a better personalized medicine.
Hassan R; Allali I; Agamah FE; Elsheikh SSM; Thomford NE; Dandara C; Chimusa ER
Brief Bioinform; 2021 Jul; 22(4):. PubMed ID: 33253350
[TBL] [Abstract][Full Text] [Related]
10. Ecophylogenetics Clarifies the Evolutionary Association between Mammals and Their Gut Microbiota.
Gaulke CA; Arnold HK; Humphreys IR; Kembel SW; O'Dwyer JP; Sharpton TJ
mBio; 2018 Sep; 9(5):. PubMed ID: 30206171
[TBL] [Abstract][Full Text] [Related]
11. The gut mycobiome of the Human Microbiome Project healthy cohort.
Nash AK; Auchtung TA; Wong MC; Smith DP; Gesell JR; Ross MC; Stewart CJ; Metcalf GA; Muzny DM; Gibbs RA; Ajami NJ; Petrosino JF
Microbiome; 2017 Nov; 5(1):153. PubMed ID: 29178920
[TBL] [Abstract][Full Text] [Related]
12. Omics for Understanding the Gut-Liver-Microbiome Axis and Precision Medicine.
Khalsa J; Duffy LC; Riscuta G; Starke-Reed P; Hubbard VS
Clin Pharmacol Drug Dev; 2017 Mar; 6(2):176-185. PubMed ID: 28263462
[TBL] [Abstract][Full Text] [Related]
13. Application of metagenomics in the human gut microbiome.
Wang WL; Xu SY; Ren ZG; Tao L; Jiang JW; Zheng SS
World J Gastroenterol; 2015 Jan; 21(3):803-14. PubMed ID: 25624713
[TBL] [Abstract][Full Text] [Related]
14. Pharmacomicrobiomics: Exploiting the Drug-Microbiota Interactions in Antihypertensive Treatment.
Chen HQ; Gong JY; Xing K; Liu MZ; Ren H; Luo JQ
Front Med (Lausanne); 2021; 8():742394. PubMed ID: 35127738
[TBL] [Abstract][Full Text] [Related]
15. Gut Reactions: Breaking Down Xenobiotic-Microbiome Interactions.
Clarke G; Sandhu KV; Griffin BT; Dinan TG; Cryan JF; Hyland NP
Pharmacol Rev; 2019 Apr; 71(2):198-224. PubMed ID: 30890566
[TBL] [Abstract][Full Text] [Related]
16. Drug pharmacomicrobiomics and toxicomicrobiomics: from scattered reports to systematic studies of drug-microbiome interactions.
Aziz RK; Hegazy SM; Yasser R; Rizkallah MR; ElRakaiby MT
Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):1043-1055. PubMed ID: 30269615
[TBL] [Abstract][Full Text] [Related]
17. From next-generation sequencing to systematic modeling of the gut microbiome.
Ji B; Nielsen J
Front Genet; 2015; 6():219. PubMed ID: 26157455
[TBL] [Abstract][Full Text] [Related]
18. Interaction between drugs and the gut microbiome.
Weersma RK; Zhernakova A; Fu J
Gut; 2020 Aug; 69(8):1510-1519. PubMed ID: 32409589
[TBL] [Abstract][Full Text] [Related]
19. Compositional variation of the human fecal microbiome in relation to azo-reducing activity: a pilot study.
Zahran SA; Ali-Tammam M; Ali AE; Aziz RK
Gut Pathog; 2021 Oct; 13(1):58. PubMed ID: 34625106
[TBL] [Abstract][Full Text] [Related]
20. Metage2Metabo, microbiota-scale metabolic complementarity for the identification of key species.
Belcour A; Frioux C; Aite M; Bretaudeau A; Hildebrand F; Siegel A
Elife; 2020 Dec; 9():. PubMed ID: 33372654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
